Given his old age and the elevated risks of cardiovascular disease, mild anemia, and stage 3 CKD in the absence of chronic comorbidities, as well as in an attempt to avoid a potential quick Hb rise in the short term, ROXA 50 mg three times weekly was prescribed (instead of 100 mg three times a week for a patient with a bodyweight of 70 kg) as a trial treatment. This evidence concerns the gene GSTM1 and anemia (phenotype).